SGLT2-Inhibitor Benefit Outweighs Ketoacidosis Risk, Says AACESGLT2-Inhibitor Benefit Outweighs Ketoacidosis Risk, Says AACE

Regulators in the US and Europe issued warnings earlier this year that the drugs may cause diabetic ketoacidosis, but in a 2-day conference, medical societies chose not to change their guidelines. Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news